FDA Approves Novartis' Adakveo for Pain Events Associated with Sickle Cell Disease
The U.S.Food and Drug Administration (FDA)approvedNovartis’ Adakveo (crizanlizumab) to decrease the frequency of vaso-occlusive crises...
top of page
Website Translator
SCDF Staff
Feb 213 min read
FDA Approves Oxbryta™, First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Oxbryta (voxelotor), a first sickle cell treatment that works to stop the sickling and destruction of red blood cells that mark this...
2650
bottom of page